Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Gradishar

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled AnalysisMelinda L Telli, Charles Chu, Sunil S Badve, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancerFrances M Boyle, Ian E Smith, Joyce O'Shaughnessy, et al.
Nature Communications|August 7, 2023
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclibR C Coombes, Sacha Howell, Simon R Lord, et al.
The Oncologist|May 24, 2021
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA TrialSara A Hurvitz, Cristina Saura, Mafalda Oliveira, et al.
Contemporary Clinical Trials|April 22, 2023
A multi-site trial of an electronic health integrated physical activity promotion intervention in breast and endometrial cancers survivors: MyActivity study protocolLisa Cadmus-Bertram, Payton Solk, Megan Agnew, et al.
Nature Communications|March 6, 2025
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclibR C Coombes, Sacha Howell, Simon R Lord, et al.
Nature Communications|July 24, 2023
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclibR C Coombes, Sacha Howell, Simon R Lord, et al.
Scientific Reports|July 26, 2023
Identification of metabolic pathways contributing to ER<sup>+</sup> breast cancer disparities using a machine-learning pipelineAshlie Santaliz-Casiano, Dhruv Mehta, Oana C Danciu, et al.
Breast Cancer Research and Treatment|October 2, 2002
Reducing disparities in breast cancer survival: a Columbia University and Avon Breast Cancer Research and Care Network SymposiumKaren Antman, Ana F Abraido-Lanza, Diane Blum, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled AnalysisMelinda L Telli, Charles Chu, Sunil S Badve, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancerFrances M Boyle, Ian E Smith, Joyce O'Shaughnessy, et al.
Nature Communications|August 7, 2023
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclibR C Coombes, Sacha Howell, Simon R Lord, et al.
The Oncologist|May 24, 2021
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA TrialSara A Hurvitz, Cristina Saura, Mafalda Oliveira, et al.
Contemporary Clinical Trials|April 22, 2023
A multi-site trial of an electronic health integrated physical activity promotion intervention in breast and endometrial cancers survivors: MyActivity study protocolLisa Cadmus-Bertram, Payton Solk, Megan Agnew, et al.
Nature Communications|March 6, 2025
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclibR C Coombes, Sacha Howell, Simon R Lord, et al.
Nature Communications|July 24, 2023
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclibR C Coombes, Sacha Howell, Simon R Lord, et al.
Scientific Reports|July 26, 2023
Identification of metabolic pathways contributing to ER<sup>+</sup> breast cancer disparities using a machine-learning pipelineAshlie Santaliz-Casiano, Dhruv Mehta, Oana C Danciu, et al.
Breast Cancer Research and Treatment|October 2, 2002
Reducing disparities in breast cancer survival: a Columbia University and Avon Breast Cancer Research and Care Network SymposiumKaren Antman, Ana F Abraido-Lanza, Diane Blum, et al.
Pageof 8